Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection - PubMed (original) (raw)
doi: 10.1038/cgt.2012.20. Epub 2012 Apr 27.
Affiliations
- PMID: 22539062
- DOI: 10.1038/cgt.2012.20
Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection
S P Grekova et al. Cancer Gene Ther. 2012 Jul.
Abstract
Rodent autonomous parvoviruses (PVs) are endowed with oncotropic properties and represent virotherapeutics with inherent oncolytic features. This work aimed to evaluate the capacity of Minute Virus of Mice (MVMp) to act as an adjuvant stimulating a mouse glioblastoma-specific immune response. MVMp was shown to induce cell death through apoptosis in glioma GL261 cells. Antigen-presenting cells (APCs) provide the initial cue for innate and adaptive immune responses, and thus MVMp-infected GL261 cells were tested for their ability to activate dendritic cells (DCs) and microglia (MG), two distinct cell types that are able to act as APCs. MG and discrete DC subsets were activated after co-culture with MVMp-infected glioma GL261 cells, as evidenced by upregulation of specific activation markers (CD80, CD86) and release of proinflammatory cytokines (tumor necrosis factor-α and interleukin-6). The in vivo analysis of immunodeficient and immunocompetent mice revealed a clear difference in their susceptibility to MVMp-mediated tumor suppression. Immunocompetent mice were fully protected from tumor outgrowth of GL261 cells infected ex vivo with MVMp. In contrast, immunodeficient animals were less competent for MVMp-dependent tumor inhibition, with only 20% of the recipients being protected, arguing for an additional immune component to allow full tumor suppression. In keeping with this conclusion, immunocompetent mice engrafted with MVMp-infected glioma cells developed a level of anti-tumor immunity with isolated splenocytes producing elevated levels of interferon-γ. In rechallenge experiments using uninfected GL261 cells, we could show complete protection against the tumor, arguing for the induction of a T-cell-mediated, tumor-specific, long-term memory response. These findings indicate that the anticancer effect of PVs can be traced back not only for their direct oncolytic effect, but also to their ability to break tumor tolerance.
Similar articles
- Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells.
Abschuetz A, Kehl T, Geibig R, Leuchs B, Rommelaere J, Régnier-Vigouroux A. Abschuetz A, et al. Cell Tissue Res. 2006 Sep;325(3):423-36. doi: 10.1007/s00441-006-0199-z. Epub 2006 May 3. Cell Tissue Res. 2006. PMID: 16699801 - Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW. Koks CA, et al. Int J Cancer. 2015 Mar 1;136(5):E313-25. doi: 10.1002/ijc.29202. Epub 2014 Sep 19. Int J Cancer. 2015. PMID: 25208916 - Humoral immune responses against minute virus of mice vectors.
Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ. Lang SI, et al. J Gene Med. 2006 Sep;8(9):1141-50. doi: 10.1002/jgm.940. J Gene Med. 2006. PMID: 16800041 - Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW. Kim Y, et al. Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953. Viruses. 2015. PMID: 26690204 Free PMC article. Review. - Evolution of oncolytic viruses: novel strategies for cancer treatment.
Atherton MJ, Lichty BD. Atherton MJ, et al. Immunotherapy. 2013 Nov;5(11):1191-206. doi: 10.2217/imt.13.123. Immunotherapy. 2013. PMID: 24188674 Review.
Cited by
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
Gujar S, Pol JG, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G, Bell JC. Gujar S, et al. Nat Protoc. 2024 Sep;19(9):2540-2570. doi: 10.1038/s41596-024-00985-1. Epub 2024 May 20. Nat Protoc. 2024. PMID: 38769145 Review. - Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype.
Vienne M, Lopez C, Lulka H, Nevot A, Labrousse G, Dusetti N, Buscail L, Cordelier P. Vienne M, et al. Mol Ther Oncol. 2024 Feb 22;32(1):200780. doi: 10.1016/j.omton.2024.200780. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596307 Free PMC article. - Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G, Walter A, Magnus CL, Rosenhammer K, Holoborodko B, Koch V, Hirsch S, Grossmann L, Li S, Knipe DM, DeLuca N, Schuler-Thurner B, Gross S, Schwertner B, Toelge M, Rohrhofer A, Stöckl S, Bauer RJ, Knoll G, Ehrenschwender M, Haferkamp S, Schmidt B, Schuster P. Lindner G, et al. Immunology. 2024 Jun;172(2):279-294. doi: 10.1111/imm.13775. Epub 2024 Mar 5. Immunology. 2024. PMID: 38444199 - Evolution of anelloviruses from a circovirus-like ancestor through gradual augmentation of the jelly-roll capsid protein.
Butkovic A, Kraberger S, Smeele Z, Martin DP, Schmidlin K, Fontenele RS, Shero MR, Beltran RS, Kirkham AL, Aleamotu'a M, Burns JM, Koonin EV, Varsani A, Krupovic M. Butkovic A, et al. Virus Evol. 2023 May 27;9(1):vead035. doi: 10.1093/ve/vead035. eCollection 2023. Virus Evol. 2023. PMID: 37325085 Free PMC article. - Oncolytic virotherapy: basic principles, recent advances and future directions.
Lin D, Shen Y, Liang T. Lin D, et al. Signal Transduct Target Ther. 2023 Apr 11;8(1):156. doi: 10.1038/s41392-023-01407-6. Signal Transduct Target Ther. 2023. PMID: 37041165 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous